{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:20:31Z","timestamp":1793578831901,"version":"4.5.0"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["310962"],"award-info":[{"award-number":["310962"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["341059"],"award-info":[{"award-number":["341059"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007417","name":"Paulon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007417","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["681712"],"award-info":[{"award-number":["681712"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831376-C"],"award-info":[{"award-number":["ADSF-21-831376-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831377-C"],"award-info":[{"award-number":["ADSF-21-831377-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["ADSF-21-831381-C"],"award-info":[{"award-number":["ADSF-21-831381-C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2017-0243"],"award-info":[{"award-number":["FO2017-0243"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2019-0228"],"award-info":[{"award-number":["FO2019-0228"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017510","name":"UK Dementia Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Detailed characterization of early pathophysiological changes in preclinical Alzheimer's disease (AD) is necessary to enable development of correctly targeted and timed disease-modifying treatments. ASIC-E4 study (\u201cBeta-Amyloid, Synaptic loss, Inflammation and Cognition in healthy <jats:italic>APOE<\/jats:italic> \u03b54 carriers\u201d) combines state-of-the-art neuroimaging and fluid-based biomarker measurements to study the early interplay of three key pathological features of AD, i.e., beta-amyloid (A\u03b2) deposition, neuroinflammation and synaptic dysfunction and loss in cognitively normal volunteers with three different levels of genetic (<jats:italic>APOE-<\/jats:italic>related) risk for late-onset AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Here, our objective is to describe the study design, used protocols and baseline demographics of the ASIC-E4 study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods\/Design<\/jats:title><jats:p>ASIC-E4 is a prospective observational multimodal imaging study performed in Turku PET Centre in collaboration with University of Gothenburg. Cognitively normal 60\u201375-year-old-individuals with known <jats:italic>APOE<\/jats:italic> \u03b54\/\u03b54 genotype were recruited via local Auria Biobank (Turku, Finland). Recruitment of the project has been completed in July 2020 and 63 individuals were enrolled to three study groups (Group 1: <jats:italic>APOE<\/jats:italic> \u03b54\/\u03b54, <jats:italic>N<\/jats:italic> = 19; Group 2: <jats:italic>APOE<\/jats:italic> \u03b54\/\u03b53, <jats:italic>N<\/jats:italic> = 22; Group 3: <jats:italic>APOE<\/jats:italic> \u03b53\/\u03b53, <jats:italic>N<\/jats:italic> = 22). At baseline, all participants will undergo positron emission tomography imaging with tracers targeted against A\u03b2 deposition (<jats:sup>11<\/jats:sup>C-PIB), activated glia (<jats:sup>11<\/jats:sup>C-PK11195) and synaptic vesicle glycoprotein 2A (<jats:sup>11<\/jats:sup>C-UCB-J), two brain magnetic resonance imaging scans, and extensive cognitive testing. In addition, blood samples are collected for various laboratory measurements and blood biomarker analysis and cerebrospinal fluid samples are collected from a subset of participants based on additional voluntary informed consent. To evaluate the predictive value of the early neuroimaging findings, neuropsychological evaluation and blood biomarker measurements will be repeated after a 4-year follow-up period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Results of the ASIC-E4 project will bridge the gap related to limited knowledge of the synaptic and inflammatory changes and their association with each other and A\u03b2 in \u201cat-risk\u201d individuals. Thorough <jats:italic>in vivo<\/jats:italic> characterization of the biomarker profiles in this population will produce valuable information for diagnostic purposes and future drug development, where the field has already started to look beyond A\u03b2.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.826423","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T06:25:19Z","timestamp":1644387919000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease \u2013 Study Protocol and Baseline Characteristics"],"prefix":"10.3389","volume":"13","author":[{"given":"Anniina","family":"Snellman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Ekblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Koivum\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noora","family":"Lindgr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouni","family":"Tuisku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Per\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lila","family":"Kallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riina","family":"Lehtonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virva","family":"Saunavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Saunavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesa","family":"Oikonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Aarnio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliisa","family":"L\u00f6yttyniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Parkkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Karrasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha O.","family":"Rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"B1","unstructured":"GauthierS\n            Rosa-NetoP\n            MoraisJA\n            WebsterC\n          World Alzheimer Report 2021 - Journey Through the Diagnosis of Dementia2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer's disease facts and figures","volume":"16","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer's disease drug development pipeline: 2021","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement."},{"key":"B4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13195-017-0297-z","article-title":"Alzheimer's disease prevention: from risk factors to early intervention","volume":"9","author":"Crous-Bou","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer's disease","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-beta and tau in Alzheimer's disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1212\/01.WNL.0000115115.98960.37","article-title":"Early abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain","volume":"62","author":"Ingelsson","year":"2004","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"B9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack CR","year":"2018","journal-title":"Alzheimers Dement."},{"key":"B10","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science."},{"key":"B11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/mp.2011.52","article-title":"APOE and Alzheimer disease: a major gene with semi-dominant inheritance","volume":"16","author":"Genin","year":"2011","journal-title":"Mol Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","article-title":"A quarter century of APOE and Alzheimer's disease: progress to date and the path forward","volume":"101","author":"Belloy","year":"2019","journal-title":"Neuron."},{"key":"B13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","article-title":"Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease","volume":"106","author":"Reiman","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.22248","article-title":"Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease","volume":"69","author":"Villemagne","year":"2011","journal-title":"Ann Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neurobiolaging.2017.09.027","article-title":"Cortical beta-amyloid burden, gray matter, and memory in adults at varying APOE epsilon4 risk for Alzheimer's disease","volume":"61","author":"Mecca","year":"2018","journal-title":"Neurobiol Aging."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnagi.2019.00014","article-title":"The Role of APOE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer's disease","volume":"11","author":"Fernandez","year":"2019","journal-title":"Front Aging Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1093\/brain\/aww349","article-title":"An early and late peak in microglial activation in Alzheimer's disease trajectory","volume":"140","author":"Fan","year":"2017","journal-title":"Brain."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/brain\/aww017","article-title":"Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging","volume":"139","author":"Hamelin","year":"2016","journal-title":"Brain"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","article-title":"Microglial activation and tau propagate jointly across braak stages","volume":"27","author":"Pascoal","year":"2021","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","article-title":"Imaging synaptic density in the living human brain","volume":"8","author":"Finnema","year":"2016","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/0271678X17724947","article-title":"Kinetic evaluation and test-retest reproducibility of [C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans","volume":"38","author":"Finnema","year":"2018","journal-title":"J Cereb Blood Flow Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","article-title":"In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET","volume":"16","author":"Mecca","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1177\/0271678X211004312","article-title":"Comparison of [C]UCB-J and [F]FDG PET in Alzheimer's disease: a tracer kinetic modeling study","volume":"41","author":"Chen","year":"2021","journal-title":"J Cereb Blood Flow Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers","volume":"48","author":"Ashton","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/joim.13332","article-title":"Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease","volume":"290","author":"Alawode","year":"2021","journal-title":"J Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-beta biomarkers for Alzheimer's disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature."},{"key":"B28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's disease neuroimaging initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA."},{"key":"B32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun."},{"key":"B34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","article-title":"Glial fibrillary acidic protein in serum is increased in Alzheimer's disease and correlates with cognitive impairment","volume":"67","author":"Oeckl","year":"2019","journal-title":"J Alzheimers Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","article-title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment","volume":"13","author":"Cicognola","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum","volume":"78","author":"Benedet","year":"2021","journal-title":"JAMA Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00259-009-1174-1","article-title":"Reproducibility of automated simplified voxel-based analysis of PET amyloid ligand [11C]PIB uptake using 30-min scanning data","volume":"36","author":"Aalto","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"B39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1212\/01.wnl.0000167607.63000.38","article-title":"A total score for the CERAD neuropsychological battery","volume":"65","author":"Chandler","year":"2005","journal-title":"Neurology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3233\/JAD-2010-100459","article-title":"CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the AddNeuroMed study","volume":"22","author":"Paajanen","year":"2010","journal-title":"J Alzheimers Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Ann Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.neurobiolaging.2017.05.008","article-title":"Applicability of [C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model","volume":"57","author":"Snellman","year":"2017","journal-title":"Neurobiol Aging."},{"key":"B43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat Rev Drug Discov."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1212\/NXI.0000000000000443","article-title":"Microglial activation, white matter tract damage, and disability in MS","volume":"5","author":"Rissanen","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrneurol.2015.177","article-title":"CAP\u2013advancing the evaluation of preclinical Alzheimer disease treatments","volume":"12","author":"Reiman","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13195-020-00633-2","article-title":"The Alzheimer's prevention initiative composite cognitive test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease","volume":"12","author":"Langbaum","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fninf.2020.00003","article-title":"Magia: robust automated image processing and kinetic modeling toolbox for PET neuroinformatics","volume":"14","author":"Karjalainen","year":"2020","journal-title":"Front Neuroinform."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e1608","DOI":"10.1212\/WNL.0000000000011612","article-title":"Association of early beta-amyloid accumulation and neuroinflammation measured with [C]PBR28 in elderly individuals without dementia","volume":"96","author":"Toppala","year":"2021","journal-title":"Neurology."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","article-title":"Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging","volume":"31","author":"Rowe","year":"2010","journal-title":"Neurobiol Aging."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/jcbfm.2012.59","article-title":"Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[C]PK11195 brain PET studies","volume":"32","author":"Yaqub","year":"2012","journal-title":"J Cereb Blood Flow Metab."},{"key":"B51","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","article-title":"PET imaging of tau deposition in the aging human brain","volume":"89","author":"Scholl","year":"2016","journal-title":"Neuron."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.826423\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T06:25:23Z","timestamp":1644387923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.826423\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":51,"alternative-id":["10.3389\/fneur.2022.826423"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.826423","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"article-number":"826423"}}